|
| | 103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024 HB4822 Introduced 2/6/2024, by Rep. Natalie A. Manley SYNOPSIS AS INTRODUCED: | | 215 ILCS 5/356z.63 | | 225 ILCS 85/3 | |
| Amends the Pharmacy Practice Act and the Illinois Insurance Code. In the definition of "practice of pharmacy", includes the ordering of testing, screening, and treatment (rather than the ordering and administration of tests and screenings) for influenza. Makes conforming changes. Effective January 1, 2025. |
| |
| | A BILL FOR |
|
|
| | HB4822 | | LRB103 37464 RTM 67587 b |
|
|
1 | | AN ACT concerning regulation. |
2 | | Be it enacted by the People of the State of Illinois, |
3 | | represented in the General Assembly: |
4 | | Section 5. The Illinois Insurance Code is amended by |
5 | | changing Section 356z.63 as follows: |
6 | | (215 ILCS 5/356z.63) |
7 | | Sec. 356z.63 356z.61 . Coverage of pharmacy testing, |
8 | | screening, vaccinations, and treatment. A group or individual |
9 | | policy of accident and health insurance or a managed care plan |
10 | | that is amended, delivered, issued, or renewed on or after |
11 | | January 1, 2025 shall provide coverage for health care or |
12 | | patient care services provided by a pharmacist if: |
13 | | (1) the pharmacist meets the requirements and scope of |
14 | | practice described in paragraph (15), (16), or (17) , or |
15 | | (18) of subsection (d) of Section 3 of the Pharmacy |
16 | | Practice Act; |
17 | | (2) the health plan provides coverage for the same |
18 | | service provided by a licensed physician, an advanced |
19 | | practice registered nurse, or a physician assistant; |
20 | | (3) the pharmacist is included in the health benefit |
21 | | plan's network of participating providers; and |
22 | | (4) reimbursement has been successfully negotiated in |
23 | | good faith between the pharmacist and the health plan. |
|
| | HB4822 | - 2 - | LRB103 37464 RTM 67587 b |
|
|
1 | | (Source: P.A. 103-1, eff. 4-27-23; revised 8-29-23.) |
2 | | Section 10. The Pharmacy Practice Act is amended by |
3 | | changing Section 3 as follows: |
4 | | (225 ILCS 85/3) |
5 | | (Section scheduled to be repealed on January 1, 2028) |
6 | | Sec. 3. Definitions. For the purpose of this Act, except |
7 | | where otherwise limited therein: |
8 | | (a) "Pharmacy" or "drugstore" means and includes every |
9 | | store, shop, pharmacy department, or other place where |
10 | | pharmacist care is provided by a pharmacist (1) where drugs, |
11 | | medicines, or poisons are dispensed, sold or offered for sale |
12 | | at retail, or displayed for sale at retail; or (2) where |
13 | | prescriptions of physicians, dentists, advanced practice |
14 | | registered nurses, physician assistants, veterinarians, |
15 | | podiatric physicians, or optometrists, within the limits of |
16 | | their licenses, are compounded, filled, or dispensed; or (3) |
17 | | which has upon it or displayed within it, or affixed to or used |
18 | | in connection with it, a sign bearing the word or words |
19 | | "Pharmacist", "Druggist", "Pharmacy", "Pharmaceutical Care", |
20 | | "Apothecary", "Drugstore", "Medicine Store", "Prescriptions", |
21 | | "Drugs", "Dispensary", "Medicines", or any word or words of |
22 | | similar or like import, either in the English language or any |
23 | | other language; or (4) where the characteristic prescription |
24 | | sign (Rx) or similar design is exhibited; or (5) any store, or |
|
| | HB4822 | - 3 - | LRB103 37464 RTM 67587 b |
|
|
1 | | shop, or other place with respect to which any of the above |
2 | | words, objects, signs or designs are used in any |
3 | | advertisement. |
4 | | (b) "Drugs" means and includes (1) articles recognized in |
5 | | the official United States Pharmacopoeia/National Formulary |
6 | | (USP/NF), or any supplement thereto and being intended for and |
7 | | having for their main use the diagnosis, cure, mitigation, |
8 | | treatment or prevention of disease in man or other animals, as |
9 | | approved by the United States Food and Drug Administration, |
10 | | but does not include devices or their components, parts, or |
11 | | accessories; and (2) all other articles intended for and |
12 | | having for their main use the diagnosis, cure, mitigation, |
13 | | treatment or prevention of disease in man or other animals, as |
14 | | approved by the United States Food and Drug Administration, |
15 | | but does not include devices or their components, parts, or |
16 | | accessories; and (3) articles (other than food) having for |
17 | | their main use and intended to affect the structure or any |
18 | | function of the body of man or other animals; and (4) articles |
19 | | having for their main use and intended for use as a component |
20 | | or any articles specified in clause (1), (2) or (3); but does |
21 | | not include devices or their components, parts or accessories. |
22 | | (c) "Medicines" means and includes all drugs intended for |
23 | | human or veterinary use approved by the United States Food and |
24 | | Drug Administration. |
25 | | (d) "Practice of pharmacy" means: |
26 | | (1) the interpretation and the provision of assistance |
|
| | HB4822 | - 4 - | LRB103 37464 RTM 67587 b |
|
|
1 | | in the monitoring, evaluation, and implementation of |
2 | | prescription drug orders; |
3 | | (2) the dispensing of prescription drug orders; |
4 | | (3) participation in drug and device selection; |
5 | | (4) drug administration limited to the administration |
6 | | of oral, topical, injectable, and inhalation as follows: |
7 | | (A) in the context of patient education on the |
8 | | proper use or delivery of medications; |
9 | | (B) vaccination of patients 7 years of age and |
10 | | older pursuant to a valid prescription or standing |
11 | | order, by a physician licensed to practice medicine in |
12 | | all its branches, except for vaccinations covered by |
13 | | paragraph (15), upon completion of appropriate |
14 | | training, including how to address contraindications |
15 | | and adverse reactions set forth by rule, with |
16 | | notification to the patient's physician and |
17 | | appropriate record retention, or pursuant to hospital |
18 | | pharmacy and therapeutics committee policies and |
19 | | procedures. Eligible vaccines are those listed on the |
20 | | U.S. Centers for Disease Control and Prevention (CDC) |
21 | | Recommended Immunization Schedule, the CDC's Health |
22 | | Information for International Travel, or the U.S. Food |
23 | | and Drug Administration's Vaccines Licensed and |
24 | | Authorized for Use in the United States. As applicable |
25 | | to the State's Medicaid program and other payers, |
26 | | vaccines ordered and administered in accordance with |
|
| | HB4822 | - 5 - | LRB103 37464 RTM 67587 b |
|
|
1 | | this subsection shall be covered and reimbursed at no |
2 | | less than the rate that the vaccine is reimbursed when |
3 | | ordered and administered by a physician; |
4 | | (B-5) following the initial administration of |
5 | | long-acting or extended-release form opioid |
6 | | antagonists by a physician licensed to practice |
7 | | medicine in all its branches, administration of |
8 | | injections of long-acting or extended-release form |
9 | | opioid antagonists for the treatment of substance use |
10 | | disorder, pursuant to a valid prescription by a |
11 | | physician licensed to practice medicine in all its |
12 | | branches, upon completion of appropriate training, |
13 | | including how to address contraindications and adverse |
14 | | reactions, including, but not limited to, respiratory |
15 | | depression and the performance of cardiopulmonary |
16 | | resuscitation, set forth by rule, with notification to |
17 | | the patient's physician and appropriate record |
18 | | retention, or pursuant to hospital pharmacy and |
19 | | therapeutics committee policies and procedures; |
20 | | (C) administration of injections of |
21 | | alpha-hydroxyprogesterone caproate, pursuant to a |
22 | | valid prescription, by a physician licensed to |
23 | | practice medicine in all its branches, upon completion |
24 | | of appropriate training, including how to address |
25 | | contraindications and adverse reactions set forth by |
26 | | rule, with notification to the patient's physician and |
|
| | HB4822 | - 6 - | LRB103 37464 RTM 67587 b |
|
|
1 | | appropriate record retention, or pursuant to hospital |
2 | | pharmacy and therapeutics committee policies and |
3 | | procedures; and |
4 | | (D) administration of injections of long-term |
5 | | antipsychotic medications pursuant to a valid |
6 | | prescription by a physician licensed to practice |
7 | | medicine in all its branches, upon completion of |
8 | | appropriate training conducted by an Accreditation |
9 | | Council of Pharmaceutical Education accredited |
10 | | provider, including how to address contraindications |
11 | | and adverse reactions set forth by rule, with |
12 | | notification to the patient's physician and |
13 | | appropriate record retention, or pursuant to hospital |
14 | | pharmacy and therapeutics committee policies and |
15 | | procedures. |
16 | | (5) (blank); |
17 | | (6) drug regimen review; |
18 | | (7) drug or drug-related research; |
19 | | (8) the provision of patient counseling; |
20 | | (9) the practice of telepharmacy; |
21 | | (10) the provision of those acts or services necessary |
22 | | to provide pharmacist care; |
23 | | (11) medication therapy management; |
24 | | (12) the responsibility for compounding and labeling |
25 | | of drugs and devices (except labeling by a manufacturer, |
26 | | repackager, or distributor of non-prescription drugs and |
|
| | HB4822 | - 7 - | LRB103 37464 RTM 67587 b |
|
|
1 | | commercially packaged legend drugs and devices), proper |
2 | | and safe storage of drugs and devices, and maintenance of |
3 | | required records; |
4 | | (13) the assessment and consultation of patients and |
5 | | dispensing of hormonal contraceptives; |
6 | | (14) the initiation, dispensing, or administration of |
7 | | drugs, laboratory tests, assessments, referrals, and |
8 | | consultations for human immunodeficiency virus |
9 | | pre-exposure prophylaxis and human immunodeficiency virus |
10 | | post-exposure prophylaxis under Section 43.5; |
11 | | (15) vaccination of patients 7 years of age and older |
12 | | for COVID-19 or influenza subcutaneously, intramuscularly, |
13 | | or orally as authorized, approved, or licensed by the |
14 | | United States Food and Drug Administration, pursuant to |
15 | | the following conditions: |
16 | | (A) the vaccine must be authorized or licensed by |
17 | | the United States Food and Drug Administration; |
18 | | (B) the vaccine must be ordered and administered |
19 | | according to the Advisory Committee on Immunization |
20 | | Practices standard immunization schedule; |
21 | | (C) the pharmacist must complete a course of |
22 | | training accredited by the Accreditation Council on |
23 | | Pharmacy Education or a similar health authority or |
24 | | professional body approved by the Division of |
25 | | Professional Regulation; |
26 | | (D) the pharmacist must have a current certificate |
|
| | HB4822 | - 8 - | LRB103 37464 RTM 67587 b |
|
|
1 | | in basic cardiopulmonary resuscitation; |
2 | | (E) the pharmacist must complete, during each |
3 | | State licensing period, a minimum of 2 hours of |
4 | | immunization-related continuing pharmacy education |
5 | | approved by the Accreditation Council on Pharmacy |
6 | | Education; |
7 | | (F) the pharmacist must comply with recordkeeping |
8 | | and reporting requirements of the jurisdiction in |
9 | | which the pharmacist administers vaccines, including |
10 | | informing the patient's primary-care provider, when |
11 | | available, and complying with requirements whereby the |
12 | | person administering a vaccine must review the vaccine |
13 | | registry or other vaccination records prior to |
14 | | administering the vaccine; and |
15 | | (G) the pharmacist must inform the pharmacist's |
16 | | patients who are less than 18 years old, as well as the |
17 | | adult caregiver accompanying the child, of the |
18 | | importance of a well-child visit with a pediatrician |
19 | | or other licensed primary-care provider and must refer |
20 | | patients as appropriate; |
21 | | (16) the ordering and administration of COVID-19 |
22 | | therapeutics subcutaneously, intramuscularly, or orally |
23 | | with notification to the patient's physician and |
24 | | appropriate record retention or pursuant to hospital |
25 | | pharmacy and therapeutics committee policies and |
26 | | procedures. Eligible therapeutics are those approved, |
|
| | HB4822 | - 9 - | LRB103 37464 RTM 67587 b |
|
|
1 | | authorized, or licensed by the United States Food and Drug |
2 | | Administration and must be administered subcutaneously, |
3 | | intramuscularly, or orally in accordance with that |
4 | | approval, authorization, or licensing; and |
5 | | (17) the ordering and administration of tests and |
6 | | screenings for SARS-CoV-2 |
| | (i) influenza, (ii) SARS-COV 2, |
7 | | and (iii) health conditions identified by a statewide |
8 | | public health emergency, as defined in the Illinois |
9 | | Emergency Management Agency Act, with notification to the |
10 | | patient's physician and appropriate record retention or |
11 | | pursuant to hospital pharmacy and therapeutics committee |
12 | | policies and procedures. Eligible tests and screenings are |
13 | | those approved, authorized, or licensed by the United |
14 | | States Food and Drug Administration and must be |
15 | | administered in accordance with that approval, |
16 | | authorization, or licensing ; and . |
17 | | (18) the ordering of testing, screening, and treatment |
18 | | for influenza. |
19 | | A pharmacist who orders testing, screening, or treatments |
20 | | or administers tests or screenings for health conditions |
21 | | described in paragraphs (17) and (18) this paragraph may use a |
22 | | test that may guide clinical decision-making for the health |
23 | | condition that is waived under the federal Clinical Laboratory |
24 | | Improvement Amendments of 1988 and regulations promulgated |
25 | | thereunder or any established screening procedure that is |
26 | | established under a statewide protocol. |
|
| | HB4822 | - 10 - | LRB103 37464 RTM 67587 b |
|
|
1 | | A pharmacist may delegate the administrative and technical |
2 | | tasks of performing a test for the health conditions described |
3 | | in paragraphs (17) and (18) this paragraph to a registered |
4 | | pharmacy technician or student pharmacist acting under the |
5 | | supervision of the pharmacist. |
6 | | A pharmacist who performs any of the acts defined as the |
7 | | practice of pharmacy in this State must be actively licensed |
8 | | as a pharmacist under this Act. |
9 | | (e) "Prescription" means and includes any written, oral, |
10 | | facsimile, or electronically transmitted order for drugs or |
11 | | medical devices, issued by a physician licensed to practice |
12 | | medicine in all its branches, dentist, veterinarian, podiatric |
13 | | physician, or optometrist, within the limits of his or her |
14 | | license, by a physician assistant in accordance with |
15 | | subsection (f) of Section 4, or by an advanced practice |
16 | | registered nurse in accordance with subsection (g) of Section |
17 | | 4, containing the following: (1) name of the patient; (2) date |
18 | | when prescription was issued; (3) name and strength of drug or |
19 | | description of the medical device prescribed; and (4) |
20 | | quantity; (5) directions for use; (6) prescriber's name, |
21 | | address, and signature; and (7) DEA registration number where |
22 | | required, for controlled substances. The prescription may, but |
23 | | is not required to, list the illness, disease, or condition |
24 | | for which the drug or device is being prescribed. DEA |
25 | | registration numbers shall not be required on inpatient drug |
26 | | orders. A prescription for medication other than controlled |
|
| | HB4822 | - 11 - | LRB103 37464 RTM 67587 b |
|
|
1 | | substances shall be valid for up to 15 months from the date |
2 | | issued for the purpose of refills, unless the prescription |
3 | | states otherwise. |
4 | | (f) "Person" means and includes a natural person, |
5 | | partnership, association, corporation, government entity, or |
6 | | any other legal entity. |
7 | | (g) "Department" means the Department of Financial and |
8 | | Professional Regulation. |
9 | | (h) "Board of Pharmacy" or "Board" means the State Board |
10 | | of Pharmacy of the Department of Financial and Professional |
11 | | Regulation. |
12 | | (i) "Secretary" means the Secretary of Financial and |
13 | | Professional Regulation. |
14 | | (j) "Drug product selection" means the interchange for a |
15 | | prescribed pharmaceutical product in accordance with Section |
16 | | 25 of this Act and Section 3.14 of the Illinois Food, Drug and |
17 | | Cosmetic Act. |
18 | | (k) "Inpatient drug order" means an order issued by an |
19 | | authorized prescriber for a resident or patient of a facility |
20 | | licensed under the Nursing Home Care Act, the ID/DD Community |
21 | | Care Act, the MC/DD Act, the Specialized Mental Health |
22 | | Rehabilitation Act of 2013, the Hospital Licensing Act, or the |
23 | | University of Illinois Hospital Act, or a facility which is |
24 | | operated by the Department of Human Services (as successor to |
25 | | the Department of Mental Health and Developmental |
26 | | Disabilities) or the Department of Corrections. |
|
| | HB4822 | - 12 - | LRB103 37464 RTM 67587 b |
|
|
1 | | (k-5) "Pharmacist" means an individual health care |
2 | | professional and provider currently licensed by this State to |
3 | | engage in the practice of pharmacy. |
4 | | (l) "Pharmacist in charge" means the licensed pharmacist |
5 | | whose name appears on a pharmacy license and who is |
6 | | responsible for all aspects of the operation related to the |
7 | | practice of pharmacy. |
8 | | (m) "Dispense" or "dispensing" means the interpretation, |
9 | | evaluation, and implementation of a prescription drug order, |
10 | | including the preparation and delivery of a drug or device to a |
11 | | patient or patient's agent in a suitable container |
12 | | appropriately labeled for subsequent administration to or use |
13 | | by a patient in accordance with applicable State and federal |
14 | | laws and regulations. "Dispense" or "dispensing" does not mean |
15 | | the physical delivery to a patient or a patient's |
16 | | representative in a home or institution by a designee of a |
17 | | pharmacist or by common carrier. "Dispense" or "dispensing" |
18 | | also does not mean the physical delivery of a drug or medical |
19 | | device to a patient or patient's representative by a |
20 | | pharmacist's designee within a pharmacy or drugstore while the |
21 | | pharmacist is on duty and the pharmacy is open. |
22 | | (n) "Nonresident pharmacy" means a pharmacy that is |
23 | | located in a state, commonwealth, or territory of the United |
24 | | States, other than Illinois, that delivers, dispenses, or |
25 | | distributes, through the United States Postal Service, |
26 | | commercially acceptable parcel delivery service, or other |
|
| | HB4822 | - 13 - | LRB103 37464 RTM 67587 b |
|
|
1 | | common carrier, to Illinois residents, any substance which |
2 | | requires a prescription. |
3 | | (o) "Compounding" means the preparation and mixing of |
4 | | components, excluding flavorings, (1) as the result of a |
5 | | prescriber's prescription drug order or initiative based on |
6 | | the prescriber-patient-pharmacist relationship in the course |
7 | | of professional practice or (2) for the purpose of, or |
8 | | incident to, research, teaching, or chemical analysis and not |
9 | | for sale or dispensing. "Compounding" includes the preparation |
10 | | of drugs or devices in anticipation of receiving prescription |
11 | | drug orders based on routine, regularly observed dispensing |
12 | | patterns. Commercially available products may be compounded |
13 | | for dispensing to individual patients only if all of the |
14 | | following conditions are met: (i) the commercial product is |
15 | | not reasonably available from normal distribution channels in |
16 | | a timely manner to meet the patient's needs and (ii) the |
17 | | prescribing practitioner has requested that the drug be |
18 | | compounded. |
19 | | (p) (Blank). |
20 | | (q) (Blank). |
21 | | (r) "Patient counseling" means the communication between a |
22 | | pharmacist or a student pharmacist under the supervision of a |
23 | | pharmacist and a patient or the patient's representative about |
24 | | the patient's medication or device for the purpose of |
25 | | optimizing proper use of prescription medications or devices. |
26 | | "Patient counseling" may include without limitation (1) |
|
| | HB4822 | - 14 - | LRB103 37464 RTM 67587 b |
|
|
1 | | obtaining a medication history; (2) acquiring a patient's |
2 | | allergies and health conditions; (3) facilitation of the |
3 | | patient's understanding of the intended use of the medication; |
4 | | (4) proper directions for use; (5) significant potential |
5 | | adverse events; (6) potential food-drug interactions; and (7) |
6 | | the need to be compliant with the medication therapy. A |
7 | | pharmacy technician may only participate in the following |
8 | | aspects of patient counseling under the supervision of a |
9 | | pharmacist: (1) obtaining medication history; (2) providing |
10 | | the offer for counseling by a pharmacist or student |
11 | | pharmacist; and (3) acquiring a patient's allergies and health |
12 | | conditions. |
13 | | (s) "Patient profiles" or "patient drug therapy record" |
14 | | means the obtaining, recording, and maintenance of patient |
15 | | prescription information, including prescriptions for |
16 | | controlled substances, and personal information. |
17 | | (t) (Blank). |
18 | | (u) "Medical device" or "device" means an instrument, |
19 | | apparatus, implement, machine, contrivance, implant, in vitro |
20 | | reagent, or other similar or related article, including any |
21 | | component part or accessory, required under federal law to |
22 | | bear the label "Caution: Federal law requires dispensing by or |
23 | | on the order of a physician". A seller of goods and services |
24 | | who, only for the purpose of retail sales, compounds, sells, |
25 | | rents, or leases medical devices shall not, by reasons |
26 | | thereof, be required to be a licensed pharmacy. |
|
| | HB4822 | - 15 - | LRB103 37464 RTM 67587 b |
|
|
1 | | (v) "Unique identifier" means an electronic signature, |
2 | | handwritten signature or initials, thumb print, or other |
3 | | acceptable biometric or electronic identification process as |
4 | | approved by the Department. |
5 | | (w) "Current usual and customary retail price" means the |
6 | | price that a pharmacy charges to a non-third-party payor. |
7 | | (x) "Automated pharmacy system" means a mechanical system |
8 | | located within the confines of the pharmacy or remote location |
9 | | that performs operations or activities, other than compounding |
10 | | or administration, relative to storage, packaging, dispensing, |
11 | | or distribution of medication, and which collects, controls, |
12 | | and maintains all transaction information. |
13 | | (y) "Drug regimen review" means and includes the |
14 | | evaluation of prescription drug orders and patient records for |
15 | | (1) known allergies; (2) drug or potential therapy |
16 | | contraindications; (3) reasonable dose, duration of use, and |
17 | | route of administration, taking into consideration factors |
18 | | such as age, gender, and contraindications; (4) reasonable |
19 | | directions for use; (5) potential or actual adverse drug |
20 | | reactions; (6) drug-drug interactions; (7) drug-food |
21 | | interactions; (8) drug-disease contraindications; (9) |
22 | | therapeutic duplication; (10) patient laboratory values when |
23 | | authorized and available; (11) proper utilization (including |
24 | | over or under utilization) and optimum therapeutic outcomes; |
25 | | and (12) abuse and misuse. |
26 | | (z) "Electronically transmitted prescription" means a |
|
| | HB4822 | - 16 - | LRB103 37464 RTM 67587 b |
|
|
1 | | prescription that is created, recorded, or stored by |
2 | | electronic means; issued and validated with an electronic |
3 | | signature; and transmitted by electronic means directly from |
4 | | the prescriber to a pharmacy. An electronic prescription is |
5 | | not an image of a physical prescription that is transferred by |
6 | | electronic means from computer to computer, facsimile to |
7 | | facsimile, or facsimile to computer. |
8 | | (aa) "Medication therapy management services" means a |
9 | | distinct service or group of services offered by licensed |
10 | | pharmacists, physicians licensed to practice medicine in all |
11 | | its branches, advanced practice registered nurses authorized |
12 | | in a written agreement with a physician licensed to practice |
13 | | medicine in all its branches, or physician assistants |
14 | | authorized in guidelines by a supervising physician that |
15 | | optimize therapeutic outcomes for individual patients through |
16 | | improved medication use. In a retail or other non-hospital |
17 | | pharmacy, medication therapy management services shall consist |
18 | | of the evaluation of prescription drug orders and patient |
19 | | medication records to resolve conflicts with the following: |
20 | | (1) known allergies; |
21 | | (2) drug or potential therapy contraindications; |
22 | | (3) reasonable dose, duration of use, and route of |
23 | | administration, taking into consideration factors such as |
24 | | age, gender, and contraindications; |
25 | | (4) reasonable directions for use; |
26 | | (5) potential or actual adverse drug reactions; |
|
| | HB4822 | - 17 - | LRB103 37464 RTM 67587 b |
|
|
1 | | (6) drug-drug interactions; |
2 | | (7) drug-food interactions; |
3 | | (8) drug-disease contraindications; |
4 | | (9) identification of therapeutic duplication; |
5 | | (10) patient laboratory values when authorized and |
6 | | available; |
7 | | (11) proper utilization (including over or under |
8 | | utilization) and optimum therapeutic outcomes; and |
9 | | (12) drug abuse and misuse. |
10 | | "Medication therapy management services" includes the |
11 | | following: |
12 | | (1) documenting the services delivered and |
13 | | communicating the information provided to patients' |
14 | | prescribers within an appropriate time frame, not to |
15 | | exceed 48 hours; |
16 | | (2) providing patient counseling designed to enhance a |
17 | | patient's understanding and the appropriate use of his or |
18 | | her medications; and |
19 | | (3) providing information, support services, and |
20 | | resources designed to enhance a patient's adherence with |
21 | | his or her prescribed therapeutic regimens. |
22 | | "Medication therapy management services" may also include |
23 | | patient care functions authorized by a physician licensed to |
24 | | practice medicine in all its branches for his or her |
25 | | identified patient or groups of patients under specified |
26 | | conditions or limitations in a standing order from the |
|
| | HB4822 | - 18 - | LRB103 37464 RTM 67587 b |
|
|
1 | | physician. |
2 | | "Medication therapy management services" in a licensed |
3 | | hospital may also include the following: |
4 | | (1) reviewing assessments of the patient's health |
5 | | status; and |
6 | | (2) following protocols of a hospital pharmacy and |
7 | | therapeutics committee with respect to the fulfillment of |
8 | | medication orders. |
9 | | (bb) "Pharmacist care" means the provision by a pharmacist |
10 | | of medication therapy management services, with or without the |
11 | | dispensing of drugs or devices, intended to achieve outcomes |
12 | | that improve patient health, quality of life, and comfort and |
13 | | enhance patient safety. |
14 | | (cc) "Protected health information" means individually |
15 | | identifiable health information that, except as otherwise |
16 | | provided, is: |
17 | | (1) transmitted by electronic media; |
18 | | (2) maintained in any medium set forth in the |
19 | | definition of "electronic media" in the federal Health |
20 | | Insurance Portability and Accountability Act; or |
21 | | (3) transmitted or maintained in any other form or |
22 | | medium. |
23 | | "Protected health information" does not include |
24 | | individually identifiable health information found in: |
25 | | (1) education records covered by the federal Family |
26 | | Educational Right and Privacy Act; or |
|
| | HB4822 | - 19 - | LRB103 37464 RTM 67587 b |
|
|
1 | | (2) employment records held by a licensee in its role |
2 | | as an employer. |
3 | | (dd) "Standing order" means a specific order for a patient |
4 | | or group of patients issued by a physician licensed to |
5 | | practice medicine in all its branches in Illinois. |
6 | | (ee) "Address of record" means the designated address |
7 | | recorded by the Department in the applicant's application file |
8 | | or licensee's license file maintained by the Department's |
9 | | licensure maintenance unit. |
10 | | (ff) "Home pharmacy" means the location of a pharmacy's |
11 | | primary operations. |
12 | | (gg) "Email address of record" means the designated email |
13 | | address recorded by the Department in the applicant's |
14 | | application file or the licensee's license file, as maintained |
15 | | by the Department's licensure maintenance unit. |
16 | | (Source: P.A. 102-16, eff. 6-17-21; 102-103, eff. 1-1-22; |
17 | | 102-558, eff. 8-20-21; 102-813, eff. 5-13-22; 102-1051, eff. |
18 | | 1-1-23; 103-1, eff. 4-27-23.) |
19 | | Section 99. Effective date. This Act takes effect January |
20 | | 1, 2025. |